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Abstract
Background: It is becoming increasingly evident that platelet chemokines are involved in distinct aspects of
atherosclerosis. The aim of this study was to examine the effects of long-term supplementation with purified
anthocyanins on platelet chemokines in hypercholesterolemic individuals and to identify correlations of decreased
platelet chemokine levels with serum lipid and inflammatory marker levels.
Methods: A total of 146 hypercholesterolemic individuals were recruited and treated with 320 mg of purified
anthocyanins (n = 73) or a placebo (n = 73) daily for 24 weeks in this randomized, double-blind, placebo-controlled trial.
Results: Anthocyanin supplementation for 24 weeks significantly decreased the plasma CXCL7 (–12.32% vs. 4.22%, P = 0.
001), CXCL5 (–9.95% vs. 1.93%, P = 0.011), CXCL8 (–6.07% vs. 0.66%, P = 0.004), CXCL12 (–8.11% vs. 5.43%, P = 0.023) and
CCL2 levels (–11.63% vs. 12.84%, P = 0.001) compared with the placebo. Interestingly, the decreases in the CXCL7 and
CCL2 levels were both positively correlated with the decreases in the serum low-density lipoprotein-cholesterol (LDL-C),
high-sensitivity C-reactive protein (hsCRP) and interleukin-1β (IL-1β) levels after anthocyanin supplementation for
24 weeks. The decrease in the CXCL8 level was negatively correlated with the increase in the how-density lipoprotein-
cholesterol (HDL-C) level and was positively correlated with the decrease in the soluble P-selectin (sP-selectin) level in
the anthocyanin group. In addition, a positive correlation was observed between the decreases in the CXCL12 and
tumornecrosis factor-α (TNF-α) levels after anthocyanin supplementation. However, the plasma CXCL4L1, CXCL1,
macrophage migration inhibitory factor (MIF) and human plasminogen activator inhibitor 1 (PAI-1) levels did not
significantly change following anthocyanin supplementation.
Conclusions: The present study supports the notion that platelet chemokines are promising targets of anthocyanins in
the prevention of atherosclerosis.
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Background
Atherosclerosis is a type of chronic inflammatory disease
resulting from disordered lipid metabolism and a mal-
adaptive inflammatory response [1, 2]. Hypercholesterol-
emia has been identified as an independent risk factor for
atherosclerosis [3] that is mainly attributed to the modula-
tion of macrophage and platelet biogenesis and activity in
early atherosclerotic lesions [4]. Numerous studies have
demonstrated that platelet chemokines play an important
role in the pathogenesis of hypercholesterolemia-induced
atherosclerotic disease [5–7]. These chemokines contrib-
ute to the recruitment of circulating leukocytes and pro-
genitor cells to the site of injured endothelium, forming a
surface on which platelets are further activated to enhance
inflammation [8, 9]. In addition, platelet chemokines have
a possible pathogenic role in interactions among platelets,
oxidized low-density lipoproteins (ox-LDLs), and periph-
eral leukocytes [10, 11]. The most abundant platelet-
derived chemokines include CXCL4 (platelet factor 4;
PF4) and CXCL7 (neutrophil-activating peptide-2; NAP-
2). Several other chemokines, such as CCL5 (regulated on
activation in normal T-cell expressed and secreted;
RANTES), CXCL5 (epithelial neutrophil-activating pep-
tide; ENA-78), CXCL12 (stromal cell-derived factor 1;
SDF-1α), CXCL1 (growth-regulated oncogene-alpha;
GRO-α), CXCL8 (interleukin-8; IL-8), CCL2 (monocyte
chemotactic protein-1; MCP-1), CXCL4L1 (PF4alt),
macrophage migration inhibitory factor (MIF) and human
plasminogen activator inhibitor 1 (PAI-1), are abundantly
released or expressed by platelets but have been primarily
identified in other cell types [12–15]. Emerging evidence
indicates that the plasma levels of some platelet chemo-
kines, such as CXCL4, CCL5, CXCL5, CXCL1, CCL2 and
CXCL8, are increased in hypercholesterolemia [16–19].
Hence, reduction of platelet chemokine levels has already
been suggested as a feasible approach for preventing and
treating atherosclerosis [20].
Numerous epidemiological and medical anthropo-
logical investigations have suggested that anthocyanins
play a protective role against atherosclerosis [21, 22].
Anthocyanins, a category of phenolic flavonoids, are
abundant in various fruits, vegetables and beverages and
are commonly consumed in the human diet [23–25].
Consumption of anthocyanins beneficially influences in-
flammatory disorders, the lipid profile, platelet activation
and obesity-related disorders [26–29]. Our previous
studies have shown that purified anthocyanin supple-
mentation reduces the levels of inflammatory biological
markers and improves serum lipids and endothelial
function [30–32]. We have also found that anthocyanins
significantly inhibit platelet activation, thrombosis, plate-
let hyperactivity [33, 34] and platelet granule secretion
of molecules such as CCL5, β-TG and soluble P-selectin
(sP-selectin), both in vitro and in vivo [35]. However, the
effects of purified anthocyanin supplementation on most
other platelet chemokines in patients with hypercholes-
terolemia have not yet been assessed.
Therefore, we designed this randomized, double-blind,
placebo-controlled, 24-week trial to investigate the ef-
fects of long-term supplementation with purified antho-
cyanins on platelet chemokines in subjects with
hypercholesterolemia. We also assessed whether de-
creased platelet chemokine levels were correlated with




A total of 150 hypercholesterolemic individuals were
recruited for this trial between November 2008 and
December 2010 in Guangzhou, Guangdong, China. The
participants were recruited from physical examination cen-
ters at three hospitals and ranged in age from 40 to 65 years
old, as previously described [32, 35]. Briefly, the clinical in-
clusion criterion for participation in the trial was a fasting
total cholesterol level of between 5.17 mmol/L and
8.01 mmol/L (approximately 200 mg/dL to 310 mg/dL). In-
dividuals with a history of cardiovascular disease (CVD),
hypertension, diabetes mellitus, thyroid disorder, smoking
or the use of any drug that could influence the measure-
ment of lipid parameters, inflammatory markers, or chemo-
kines were excluded from the study. The study was
approved by the ethics committee of Sun Yat-sen University
(the protocol number is No. 200802; the clinical trial num-
ber is ChiCTR-TRC-08000240), and written informed con-
sent was obtained from all participants.
Study design
This randomized, double-blind, placebo-controlled trial
was carried out for 24 weeks. Briefly, the participants
were randomly assigned to either an anthocyanin group
(n = 75; 31 males and 44 females) or a placebo group (n
= 75; 32 males and 43 females). During the trial period,
the participants were instructed to consume two antho-
cyanin capsules or placebo capsules twice daily for
24 weeks. The anthocyanin capsules provided a total
daily intake of 320 mg of anthocyanins. The participants
were told not to change their dietary habits and not to
consume any anthocyanin-rich foods or any other medi-
cations that might affect the serum anthocyanin level
over the following 24 weeks. Fasting blood samples
(≥10 h) were collected at the beginning and at weeks 12
and 24 of the trial.
Materials and reagents
The anthocyanin and placebo capsules were obtained
from Polyphenols AS (Sandnes, Norway). CXCL7 human
ELISA kits were purchased from Abcam (Cambridge,
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UK), and human CXCL8 and CCL2 ELISA kits were
purchased from eBioscience (San Diego, CA, USA). In
addition, MILLIPLEX Multi-analyte Profiling (MAP)
Human Cytokine/Chemokine Kits for human CXCL12,
CXCL5 and PAI-1 were purchased from Millipore
(Billerica, MA, USA). Further, human CXCL1 and MIF
ELISA kits were obtained from R&D Systems (Minneap-
olis, MN, USA) and human CXCL4L1 ELISA kits were
obtained from LifeSpan Biosciences (Denver, CO, USA).
Biochemical analysis
Fasting blood samples were collected at baseline and
weeks 12 and 24. Blood samples were drawn into hep-
arin anticoagulant tubes for all study participants early
in the morning after they had fasted overnight for 12 h,
and the samples were centrifuged at 1500 × g for 15 min
at 4 °C within 2 h to separate the plasma. Then, the
plasma was stored at –80 °C until testing. The concen-
trations of serum lipids, including total cholesterol,
triglycerides, low-density lipoprotein cholesterol (LDL-
C) and high-density lipoprotein cholesterol (HDL-C),
were measured enzymatically using an automatic
analyzer. The serum high-sensitivity C-reactive protein
(hsCRP) levels were determined using a Hitachi 911 au-
tomated assay analyzer and the immunoturbidimetric
method. The serum tumornecrosis factor-α (TNF-α)
level was measured using a commercially available
ELISA kit obtained from R&D Systems (Minneapolis,
MN, USA). Further, the plasma interleukin-1β (IL-1β)
and sP-selectin levels were measured with commercial
ELISA kits obtained from eBioscience (San Diego, CA,
USA) as previously described [32, 35].
Analysis of platelet chemokine levels
Platelet chemokines levels in the plasma were quantified
using commercial ELISA kits or MILLIPLEX MAP Hu-
man Cytokine/Chemokine Kits. The samples used in
ELISA were diluted based on the pre-experiment con-
centrations and were run in duplicate in accordance
with the manufacturer's instructions. The recombinant
products and standard solutions provided in the kits
were used as positive controls. The optical density of
each well was determined at 450 nm using a plate reader
within 30 min. Average absorbance values were calcu-
lated for each set of duplicate standards and samples.
The data were analyzed based on the standard curve
values. Multiplex immune assays were performed ac-
cording to the manufacturer's instructions.
Statistical analysis
The platelet chemokine data were expressed as the mean
± SD or as the mean and 95% confidence interval (CI).
The baseline characteristics of the two groups were com-
pared using unpaired Student's t-test for continuous data.
Further, repeated-measures ANCOVA was conducted to
determine the effects of anthocyanin supplementation on
platelet chemokines in the hypercholesterolemic subjects.
The percentage changes in the platelet chemokine levels
were calculated as follows: (value at week 24 – value at
baseline)/value at baseline × 100. The average percentage
change was expressed as the mean (95% CI). Differences
in the average percentage changes in the platelet chemo-
kine levels between the two groups were evaluated using
unpaired Student's t-test. Comparisons of the absolute
changes in the platelet chemokine levels after the 24-week
intervention within the groups were conducted using
paired Student's t-test. In addition, Pearson correlation
coefficients (r) were calculated to assess the associations
between the decreased plasma chemokine concentrations
and the changes in the plasma lipid and inflammatory
maker levels over the 24-week study period. Differences
were considered significant at a P < 0.05. All statistical
analyses were performed using IBM SPSS Statistics 20
(SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of the subjects
A total of 4 participants withdrew from this trial, and
146 subjects ultimately completed it (n = 73 in the
anthocyanin group; and n = 73 in the placebo group).
The distributions of age, the anthropometric characteris-
tics and the mean daily intake of nutrients were uniform
between the two groups, as previously described
(Table 1) [32]. No subjects reported any adverse events
resulting from the treatment throughout the interven-
tion period.
Effects of anthocyanin supplementation on platelet
chemokines
The plasma platelet chemokine concentrations at baseline
and at weeks 12 and 24 after the intervention are shown
in Table 2. No significant differences in these concentra-
tions were observed between the two groups at baseline.
At week 12, only the plasma CXCL5 (P = 0.021) and
CXCL8 concentrations (P = 0.015) were significantly
decreased by anthocyanins compared with the baseline
concentrations. At week 24, anthocyanin supplementation
resulted in significant decreases in the plasma CXCL7
[–12.32% (95% CI, –19.25 to –5.00%), P = 0.001], CXCL5
[–9.95% (95% CI, –15.84 to –3.56%), P = 0.011], CXCL8
[–6.07% (95% CI, –8.15 to –4.23%), P = 0.004], CXCL12
[–8.11% (95% CI, –15.98 to –0.30%), P = 0.023] and CCL2
concentrations [–11.63% (95% CI, –18.16 to –4.85%), P =
0.001] compared with the placebo. Although the plasma
CXCL4L1, CXCL1, MIF and PAI-1 concentrations also
exhibited trends toward slight decreases during the
treatment period, no significant changes were detected
between the two groups.
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Effects of anthocyanin supplementation on serum lipids
The serum lipid levels at baseline and 24 weeks are listed in
Table 3, as previously described [32]. In the anthocyanin
group, the HDL-C level significantly increased from 1.22
(0.23) mmol/L at baseline to 1.37 (0.22) mmol/L at week
24 (P = 0.018), accompanied by a significant reduction in
the LDL-C level from 3.36 (0.58) mmol/L to 3.01 (0.41)
mmol/L (P = 0.038). Moreover, significant differences in the
HDL-C (P = 0.036) and LDL-C levels (P = 0.030) were de-
tected between the two groups after 24 weeks.
Effects of anthocyanin supplementation on serum
inflammatory biomarkers
The serum levels of the inflammatory molecules hsCRP,
TNF-α, IL-1β and sP-selectin in the participants at base-
line and at weeks 12 and 24 are summarized in Table 4,
as previously described [32, 35]. The hsCRP and IL-1β
levels were reduced by anthocyanin supplementation at
weeks 12 and 24, respectively, compared with the base-
line levels. Further, anthocyanin supplementation for
24 weeks led to significant decreases in the plasma hsCRP
[–21.6% (95% CI, –37.5 to –5.7%)], IL-1β [–12.8% (95%
CI, –24.4 to –1.2%)], and sP-selectin levels [–5.9% (95%
CI, –17.7 to 6.0%)] compared with the placebo.
Correlations between alterations in plasma platelet
chemokine and serum lipid levels
After 24 weeks of anthocyanin supplementation, the
changes in the plasma CCL2 (r = 0.545, P < 0.001) (Fig. 1a)
and CXCL7 levels (r = 0.395, P = 0.001) (Fig. 1b) were posi-
tively correlated with the change in the LDL-C level. In
addition, the change in the CXCL8 level (r =–0.517,
P < 0.001) (Fig. 1c) was negatively correlated with the
change in the HDL-C level in the anthocyanin group.
Correlations between alterations in plasma platelet
chemokine levels and serum inflammatory biomarker
levels
After 24 weeks of anthocyanin intervention, the change
in the plasma CXCL7 level exhibited a positive correl-
ation with the changes in the hsCRP (r = 0.479, P <
0.001) (Fig. 2a) and IL-1β levels (r = 0.455, P < 0.001)
(Fig. 2b). Interestingly, the change in the CCL2 level was
also positively correlated with the changes in the hsCRP
(r = 0.399, P < 0.001) (Fig. 2c) and IL-1β levels (r = 0.474,
P < 0.001) (Fig. 2d). Furthermore, the change in the
plasma CXCL12 level was significantly correlated with
the change in the TNF-α level (r = 0.464, P < 0.001)
(Fig. 2e). In addition, a positive correlation was detected
between the changes in the CXCL8 and sP-selectin
levels (r = 0.448, P < 0.001) (Fig. 2f ) after anthocyanin
intervention for 24 weeks.
Discussion
Platelet chemokines are involved in inflammatory reac-
tions, immune responses, and other aspects of the devel-
opment of atherosclerosis [36]. In the present study, we
first demonstrated that the plasma levels of the platelet
Table 1 Anthropometric characteristics and daily nutrient intake of the participants
Placebo (n = 73) Anthocyanins (n = 73) P-valuea
Baseline 12 wk 24 wk Baseline 12wk 24 wk
Weight (kg) 70.1 ± 9.8 69.7 ± 9.9 69.5 ± 9.6 68.9 ± 8.8 67.8 ± 8.9 66.5 ± 8.1 0.342
BMI (kg/m2) 26.8 ± 2.0 26.7 ± 2.1 26.8 ± 2.2 26.4 ± 2.1 25.9 ± 2.0 26.1 ± 2.0 0.063
Waist circumference (cm) 89.6 ± 7.9 89.5 ± 8.2 89.2 ± 8.3 88.6 ± 6.4 87.4 ± 6.4 87.2 ± 6.5 0.226
Hip circumference (cm) 100.3 ± 6.3 100.3 ± 6.5 101.4 ± 6.4 100.0 ± 5.0 99.1 ± 5.2 98.3 ± 4.6 0.308
Waist/hip ratio 0.89 ± 0.06 0.89 ± 0.06 0.88 ± 0.05 0.89 ± 0.05 0.88 ± 0.05 0.88 ± 0.05 0.624
Systolic BP (mmHg) 124.3 ± 16.0 123.8 ± 15.0 120.7 ± 15.1 126.2 ± 14.9 119.5 ± 12.5 119.4 ± 12.6 0.135
Diastolic BP(mmHg) 82.8 ± 10.5 81.2 ± 9.1 81.1 ± 9.8 84.7 ± 10.7 82.8 ± 9.6 82.6 ± 9.3 0.219
Energy (kcal/d) 2163.6 ± 124.2 2168.2 ± 116.1 2154.4 ± 114.2 2185.4 ± 132.5 2199.2 ± 123.7 2171.6 ± 121.8 0.684
Protein (g/d) 84.8 ± 10.8 83.6 ± 9.4 81.4 ± 9.5 85.7 ± 10.5 84.5 ± 9.8 86.5 ± 10.9 0.702
% of energy 18.5 ± 3.1 18.4 ± 2.7 17.3 ± 3.0 18.6 ± 2.9 18.5 ± 3.1 19.1 ± 3.2 0.746
Total fat (g/d) 82.4 ± 18.2 80.1 ± 17.2 80.2 ± 16.8 80.2 ± 15.8 83.7 ± 17.6 84.9 ± 18.1 0.282
% of energy 26.5 ± 3.5 26.3 ± 3.2 24.3 ± 4.0 26.4 ± 3.2 27.4 ± 4.0 27.6 ± 4.3 0.493
Total carbohydrates (g/d) 258.6 ± 34.2 258.8 ± 40.5 261.0 ± 39.7 262.1 ± 43.8 263.2 ± 42.5 260.4 ± 40.3 0.161
% of energy 55.2 ± 4.7 55.3 ± 4.6 56.9 ± 4.5 55.0 ± 5.3 55.3 ± 4.8 54.2 ± 4.2 0.824
Cholesterol (mg/d) 339.4 ± 43.2 340.1 ± 38.4 331.3 ± 40.4 341.3 ± 40.2 342.5 ± 39.3 340.7 ± 43.6 0.327
Fiber (g/d) 20.5 ± 4.4 20.8 ± 4.2 19.2 ± 4.0 20.6 ± 5.0 20.6 ± 4.5 21.3 ± 4.7 0.644
The data are expressed as the mean ± SD
No significant differences in any variable were observed between the two groups at baseline, as determined using unpaired Student’s t-test
aThe intervention had no significant effects on daily nutrient intake, as determined by repeated-measures ANOVA
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Table 2 Changes in the platelet chemokine levels in the participants
Placebo (n = 73) Anthocyanins (n = 73) P-valueb
Baseline 12 wk 24 wk Mean change,% (95% CI)a Baseline 12 wk 24 wk Mean change,% (95% CI)a
CXCL7 (ng/ml) 167.63 ± 38.78 165.82 ± 37.83 166.20 ± 31.92 4.22 170.52 ± 44.86 157.76 ± 43.21 138.83 ± 30.49c −12.32 0.011
(−2.33 to 11.05) (−19.25 to −5.00)d
CXCL5 (pg/ml) 159.43 ± 29.35 157.85 ± 31.80 157.32 ± 29.74 1.93 160.40 ± 36.26 150.78 ± 28.98 c 137.61 ± 26.14c −9.95 0.006
(−4.18 to 9.28) (−15.84 to −3.56)d
CXCL8 (pg/ml) 22.97 ± 2.73 22.91 ± 2.51 22.97 ± 4.24 0.66 22.93 ± 1.96 22.32 ± 1.61 c 21.40 ± 1.07c −6.07 0.016
(−2.99 to 4.88) (−8.15 to −4.23)d
CXCL12 (ng/mL) 2.16 ± 0.53 2.15 ± 0.51 2.14 ± 0.46 5.43 2.19 ± 0.56 2.11 ± 0.34 1.86 ± 0.47c −8.11 0.020
(−2.03 to 14.16) (−15.98 to −0.30)d
CCL2 (pg/mL) 504.99 ± 165.34 502.68 ± 157.33 515.76 ± 132.04 12.84 502.97 ± 139.91 476.96 ± 113.74 414.61 ± 87.14c −11.63 0.014
(1.05 to 27.23) (−18.16 to −4.85)d
CXCL4L1 (pg/ml) 124.29 ± 88.87 134.00 ± 69.82 135.16 ± 75.07 0.08 126.52 ± 67.05 126.44 ± 75.21 112.27 ± 86.78 −0.80 0.769
(−0.21 to 0.35) (−2.07 to 0.06)
CXCL1 (ng/ml) 20.96 ± 3.15 21.94 ± 2.38 22.92 ± 3.67 0.07 21.30 ± 4.71 21.00 ± 3.37 21.07 ± 1.79 −0.02 0.529
(−0.06 to 0.19) (−0.24 to 0.16)
PAI-1 (ng/ml) 101.52 ± 41.81 106.13 ± 48.55 108.84 ± 14.31 0.08 104.07 ± 52.84 107.16 ± 36.38 99.62 ± 42.35 −0.44 0.888
(−0.10 to 0.29) (−1.34 to 0.20)
MIF (ng/ml) 32.91 ± 10.02 30.46 ± 9.54 29.51 ± 14.58 −9.90 32.69 ± 13.94 31.26 ± 8.53 26.93 ± 10.56 2.65 0.801
(−25.96 to 7.13) (−32.90 to 39.14)
The data are expressed as the mean ± SD
No significant differences in any variable were observed between the two groups at baseline, as determined using unpaired Student’s t-test
aCalculated as (value at week 24 – value at baseline)/value at baseline × 100
bThe effects of the intervention on these variables were evaluated by repeated-measures ANOVA
cP < 0.05 vs. baseline, as assessed by paired Student’s t-test













chemokines CXCL7, CXCL5, CXCL8, CXCL12 and
CCL2 were significantly decreased in hypercholester-
olemic subjects after anthocyanin supplementation
for 24 weeks. Furthermore, we found that the de-
creased levels of some platelet chemokines after
anthocyanin treatment were closely correlated with
the serum lipid and inflammatory molecule levels.
These results indicated that anthocyanins exerted
beneficial effects on the platelet chemokine levels,
serum lipids and inflammatory factors, thereby inhi-
biting atherosclerosis.
Upon activation, platelets release a number of chemo-
kines that may play important roles as first-line inflamma-
tory mediators [37]. The most abundant platelet chemokine
is CXCL7, which recruits and activates neutrophils at sites
of vessel wall injury, inducing the inflammatory response
within the atherosclerotic plaque [38]. CXCL5 has been
shown to be abundantly produced and secreted by activated
platelets, thereby attracting neutrophils, enhancing the
cholesterol efflux capacity of macrophages and regulating
foam cell formation [39–41]. CXCL12 plays an important
role in leukocyte recruitment and neointima formation at
sites of arterial injury [42]. Ahmed et al. have shown that
epigallocatechin-3-gallate (EGCG) (10–50 μM), an active
constituent in green tea, significantly inhibits the IL-1β-
induced production of CXCL5, CCL5 and CXCL1 incu-
bated with rheumatoid arthritis synovial fibroblasts in
serum-free medium for 12 h [43]. Other polyphenols, such
as wogonin [44], flavonoid naringenin [45] and quercetin
[46], have been showed to inhibit CXCL5 in vitro. However,
no study has examined the effects of anthocyanins on
CXCL7, CXCL5 or CXCL12 to date. In the present study,
we first showed that long-term supplementation with puri-
fied anthocyanins reduced the plasma levels of the platelet
chemokines CXCL7, CXCL5 and CXCL12 in subjects with
hypercholesterolemia. The role of anthocyanins in reducing
platelet chemokine levels may contribute to their beneficial
effects in hypercholesterolemic subjects.
In hypercholesterolemia, surface-adherent platelets ex-
press CXCL8 or CCL2 to recruit leukocytes, which ad-
here to the denuded artery and contribute to neointimal
lesion formation [47, 48]. Recently, Karlsen et al. have
demonstrated that the plasma CXCL8 level is decreased
in healthy adults after supplementation with purified an-
thocyanins (300 mg/d) for 3 weeks [49]. Further, Kuntz
et al. have revealed that treatment with an anthocyanin-
rich grape extract for 4 h significantly attenuates CXCL8
secretion in activated human umbilical vein endothelial
cells (HUVECs) [50]. In addition, administration of an
anthocyanin-rich black elderberry extract (13% anthocy-
anins) for 10 weeks has been shown to significantly
lower the serum chemokine CCL2 level in hyperlipid-
emic mice compared with control mice [51]. Garcia-
Alonso et al. have shown that the circulating plasma
CCL2 level is decreased in healthy volunteers after treat-
ment with 12 g anthocyanin extract from red wine for
24 h [52]. Moreover, Björk et al. have found that CCL2
secretion by human primary fat cells is suppressed fol-
lowing treatment with the anthocyanin cyanidin-3-
glucoside (130 nM) for 48 h [53]. In contrast, another
study conducted by Kuntz et al. has revealed that in
healthy young female volunteers, the CXCL8 and CCL2
levels are not affected by consumption of 330 ml/d of
anthocyanin-rich fruit beverages for 14 days [54]. These
inconsistencies among studies may be related to differ-
ences in the dose of anthocyanins used, the duration of
the intervention and the study subjects. Our study is the
first to show the long-term effects of purified anthocya-
nins on CXCL8 and CCL2 in Chinese individuals with
hypercholesterolemia. These results represent novel, po-
tentially valuable evidence supporting the beneficial ef-
fects of anthocyanins on CXCL8 and CCL2.
Table 3 Changes in the lipid profiles of the participants
Placebo (n = 73) Anthocyanins (n = 73) P-valueb
Baseline 24 wk Mean change, %
(95% CI)a




6.48 ± 0.84 6.25 ± 0.83 −3.6 (−7.8 to 0.6) 6.45 ± 1.02 6.18 ± 0.82 −2.9 (−6.3 to 0.5) 0.556
HDL-cholesterol
(mmol/L)
1.24 ± 0.21 1.23 ± 0.20 −0.9 (−5.2 to 3.4) 1.22 ± 0.23 1.37 ± 0.22c 14.0 (7.9 to 20.2)d 0.036
LDL-cholesterol
(mmol/L)
3.29 ± 0.47 3.30 ± 0.52 0.3 (−2.9 to 3.5) 3.36 ± 0.58 3.01 ± 0.41c −10.4 (−14.8 to 6.0)d 0.030
Triacylglycerol
(mmol/L)
2.41 (1.47 to 2.70) 2.34 (1.35 to 2.62) −3.2 (−7.6 to 1.2) 2.45 (1.53 to 2.74) 2.35 (1.37 to 2.61) −4.8 (−9.8 to 0.2) 0.462
The data are expressed as the mean ± SD
No significant differences in any variable were observed between the two groups at baseline, as determined using unpaired Student’s t-test
a Calculated as (value at week 24 – value at baseline)/value at baseline × 100
b The effects of the intervention on these variables were evaluated by repeated-measures ANOVA
c P < 0.05 vs. baseline, as assessed by paired Student’s t-test
d P < 0.05 vs. percentage changes in the placebo group, as assessed by unpaired Student’s t-test
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Table 4 Changes in the inflammatory cytokine levels in the participants
Placebo (n = 73) Anthocyanin (n = 73) P-valueb
Baseline 12 wk 24 wk Mean change, % (95% CI)a Baseline 12 wk 24 wk Mean change, % (95% CI)a
hsCRP (mg/L) 2.26 2.23 2.19 −2.5 2.25 1.95 1.74 −21.6 0.001
(0.97 to 3.72) (1.08 to 3.76) (0.93 to 3.82) (−7.0 to 2.1) (1.06 to 4.25) (0.92 to 2.84)c (0.86 to 2.60) (–37.5 to –5.7)d
TNF-α (pg/mL) 18.0 ± 6.0 19.1 ± 6.7 18.5 ± 5.4 2.8 (−3.4 to 9.1) 18.7 ± 6.4 17.9 ± 5.1 18.4 ± 5.6 −1.6 (−5.6 to 3.4) 0.673
IL-1β (pg/mL) 4.77 ± 1.71 4.23 ± 0.91 4.71 ± 1.60 −1.3 (−5.3 to 2.7) 5.18 ± 2.11 4.62 ± 1.20c 4.51 ± 1.60c −12.8 (−24.4 to −1.2)d 0.019
sP-selectin (ng/mL) 149.9 ± 42.7 139.9 ± 39.0 139.9 ± 39.0 −2.4 (−15.4 to 10.6) 150.9 ± 37.0 144.4 ± 35.3 134.6 ± 32.8 −5.9 (−17.7 to 6.0)d 0.027
The data are expressed as the mean ± SD
No significant differences in any variable were observed between the two groups at baseline, as determined using unpaired Student’s t-test
a Calculated as (value at week 24 – value at baseline)/value at baseline × 100
b The effects of the intervention on these variables were evaluated by repeated-measures ANOVA
c P < 0.05 vs. baseline, as assessed by paired Student’s t-test













In addition to the above mentioned platelet chemo-
kines, platelets also secrete CXCL1, CXCL4L1, MIF and
PAI-1, which are crucially involved in interactions with
platelets, leukocytes and endothelial cells during the
early stage of atherogenesis [55, 56]. In an ApoE*3Leiden
mouse model, administration of an anthocyanin-rich ex-
tract, Mirtoselect (the original standardized bilberry ex-
tract), for 20 weeks has been shown to attenuate the
high-cholesterol diet-induced increase in the CXCL1
level [57]. Similarly, Jiang et al. have found that adminis-
tration of anthocyanins from purple sweet potato and
purple potato (5 mg/kg) to Kunming mice for 5 weeks
inhibits the increased CXCL1 mRNA expression induced
by alcohol [58]. Another animal study has revealed that
administration of ≥5% Saskatoon berry powder to leptin
receptor-deficient mice for 4 weeks suppresses the in-
crease in the PAI-1 level [59]. Further, Lamy et al. have
shown that delphinidin down-regulates the PAI-1 level
in glioblastoma cells [60]. Broekhuizen et al. have found
that the MIF and CCL2 levels are reduced following
consumption of a polyphenol-rich extract (500 mg daily)
for 4 weeks in subjects with clustered cardiometabolic
risk factors [61]. In contrast with the above results, an-
other study has shown that administration of an
anthocyanin-rich black elderberry extract (0.17% antho-
cyanin, w/w) for 16 weeks does not decrease the serum
PAI-1 level in diet-induced obese mice [62]. However,
no studies have examined the effects of purified antho-
cyanins on these platelet chemokines in individuals with
hypercholesterolemia. In our study, the CXCL1,
CXCL4L1, MIF and PAI-1 levels were not significantly
altered after anthocyanin supplementation for 24 weeks,
although slight decreases were observed. Therefore, we
speculate that these chemokines may not be sensitive to
anthocyanins in hypercholesterolemic patients or that
these patients may require a larger intervention dose or
a longer intervention period to observe the significant
inhibitory effects of anthocyanins.
Hypercholesterolemia is associated with elevated levels
of peripheral leukocytes, platelets and cholesterol-
induced pro-inflammatory cytokines [63]. Evidence sug-
gests that platelet chemokines are involved in interac-
tions between ox-LDL, platelets and leukocytes, possible
contributing to atherogenesis in hypercholesterolemia
[64, 65]. The primary platelet chemokines CXCL4 and
CCL2 have been demonstrated to co-localize with ox-
LDL in atherosclerotic lesions and to facilitate ox-LDL
uptake by monocytes [66, 67]. In addition, platelet che-
mokines are produced following stimulation of TNF-α
and IL-1β [68], which result in recruitment of leukocytes
to the site of vascular injury and enhancement of inflam-
matory processes. Recently, some studies have revealed
that anthocyanin supplementation significantly reduces
the serum lipid [69] and pro-inflammatory cytokine
Fig. 1 Significant correlations between changes in plasma platelet
chemokine and serum lipid levels. After 24 weeks, correlations were
detected between the changes in the plasma CCL2 (a) and CXCL7
levels (b) and the change in the LDL-C level, as well as between the
changes in the plasma CXCL8 (c) and HDL-C levels, in the anthocyanin
group. The data were evaluated using Pearson correlation
coefficients (r)
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levels [70–72], consistent with the effects of anthocya-
nins observed in our previous studies [32, 35]. In the
present study, we first revealed that the reductions in
the platelet chemokine levels caused by anthocyanins
were positively correlated with the changes in the in-
flammatory marker and blood lipid levels. In particular,
the decrease in the level of CXCL7, which is only se-
creted by platelets, was positively correlated with the de-
creases in the LDL-C, hsCRP and IL-1β levels. These
findings indicate a potential mechanism by which antho-
cyanins exert protective effects on the cardiovascular
system, achieved through the comprehensive regulation
of platelet chemokines, lipid metabolism and inflamma-
tion, in which platelet chemokines may play pivotal
roles. Selective interference with these functional inter-
actions of platelet chemokines may thus enable the
development of customized treatments for specific in-
flammatory conditions associated with CVDs.
Chemokines interact with their target cells by binding to
G protein-coupled receptors to initiate inflammatory re-
sponses [73]. Both chemokines and their receptors are the
key mediators of inflammatory processes regulating
leukocyte extravasation and directional migration to
vascular lesions [74–76]. We suspected that chemokine
receptors might be among the targets of anthocyanins.
Based on this hypothesis, we conducted an in vitro experi-
ment to explore the effects of anthocyanins on platelet
chemokine receptors. Interestingly, our primary data
showed that anthocyanins significantly inhibited the
expression of CXCR2, CXCR4 and CCR5 on leukocytes
and platelets (unpublished data). These results indicate
that inhibition of the corresponding chemokine receptors
Fig. 2 Significant correlations between changes in plasma platelet chemokine levels and inflammatory biomarker levels. After 24 weeks,
correlations were detected between the change in the plasma CXCL7 level and the changes in the hsCRP (a) and IL-1β levels (b); between the
change in the plasma CCL2 level and the changes in the hsCRP (c) and IL-1β levels (d); between the changes in the plasma CXCL12 and TNF-α
levels (e); and between the changes in the plasma CXCL8 and sP-selectin levels (f) in the anthocyanin group. The data were evaluated using Pearson
correlation coefficients (r)
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may be one of the mechanisms of anthocyanins in redu-
cing inflammatory cell recruitment. In addition, some
studies have shown that platelet chemokines promote the
recruitment of inflammatory cells to injured tissues by
forming heterocomplexes with molecules released from
neutrophils and other cells, such as HNP1-CCL5 [77],
HMGB1-CXCL12 [78], and CXCL4-CCL5 [79]. Hence,
selective disruption of the formation of these heterocom-
plexes may represent a novel mechanism of action of
anthocyanins in weakening the interactions between plate-
lets and other inflammatory cells. Further studies are
required to investigate the mechanisms underlying the
effects of anthocyanins.
Conclusions
In conclusion, the results of this study suggest that
platelet chemokines may be important targets of antho-
cyanins in prevention of the development of early ath-
erosclerosis. Anthocyanins exert their cardiovascular
protective effects by influencing platelet chemokines,
blood lipids and the inflammatory response.
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